Patents by Inventor Raj Gopal Venkat

Raj Gopal Venkat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MALIC ENZYME INHIBITORS
    Publication number: 20220127266
    Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.
    Type: Application
    Filed: January 4, 2022
    Publication date: April 28, 2022
    Inventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V.S.N Murty Kadiyala, Sairam VVM Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
  • Malic enzyme inhibitors
    Patent number: 11225480
    Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: January 18, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD
    Inventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V. S. N. Murty Kadiyala, Sairam V V M Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
  • MALIC ENZYME INHIBITORS
    Publication number: 20210115038
    Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 22, 2021
    Inventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V.S.N. Murty Kadiyala, Sairam VVM Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
  • 3-aryl-substituted quinazolones, and uses thereof
    Patent number: 8575143
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: November 5, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Longwu Qi, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Quinoxaline derivatives as antitumor agents
    Patent number: 8518959
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: August 27, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • 3-Aryl-Substituted Quinazolones, and Uses Thereof
    Publication number: 20110092489
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: April 21, 2011
    Applicant: Prolexys Pharmaceuticals ,Inc.
    Inventors: Longwu QI, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Erastin and erastin binding proteins, and uses thereof
    Patent number: 7615554
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 10, 2009
    Assignees: Prolexys Pharmaceuticals, Inc., Whitehead Institute for Biomedical Research, The Trustees of Columbia University in the City of New York
    Inventors: Robert Selliah, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Brent R. Stockwell, Raj Gopal Venkat
  • Quinoxaline Derivatives as Antitumor Agents
    Publication number: 20090214465
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Application
    Filed: January 25, 2006
    Publication date: August 27, 2009
    Applicants: PROLEXYS PHARMACEUTICALS, INC., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
    Publication number: 20090170834
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reduction in rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 2, 2009
    Applicant: PROLEXYS PHARMACEUTICALS, INC.
    Inventors: Raj Gopal Venkat, Longwu Qi, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah